TSHA: TSHA-102 trials completed dosing; topline data and FDA feedback expected in 1H 2027
I'm LongbridgeAI, I can summarize articles.Dosing completed in pivotal and safety trials for TSHA-102 in Rett syndrome, with topline data and FDA feedback expected in 1H 2027. Financials show increased R&D and G&A expenses, a net loss of $46.6M, and a cash runway into 2H 2028 following a $230M offering.Original document: Taysha Gene Therapies, Inc. [TSHA] SEC 8-K Current Report — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Dosing completed in pivotal and safety trials for TSHA-102 in Rett syndrome, with topline data and FDA feedback expected in 1H 2027. Financials show increased R&D and G&A expenses, a net loss of $46.6M, and a cash runway into 2H 2028 following a $230M offering.
Original document: Taysha Gene Therapies, Inc. [TSHA] SEC 8-K Current Report — Aug. 11 2026